Olema Pharmaceuticals Inc (OLMA) - Net Assets
Based on the latest financial reports, Olema Pharmaceuticals Inc (OLMA) has net assets worth $307.49 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($352.45 Million) and total liabilities ($44.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Olema Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $307.49 Million |
| % of Total Assets | 87.24% |
| Annual Growth Rate | N/A |
| 5-Year Change | 20.95% |
| 10-Year Change | N/A |
| Growth Volatility | 36.28 |
Olema Pharmaceuticals Inc - Net Assets Trend (2018–2024)
This chart illustrates how Olema Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore OLMA current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Olema Pharmaceuticals Inc (2018–2024)
The table below shows the annual net assets of Olema Pharmaceuticals Inc from 2018 to 2024. For live valuation and market cap data, see market value of Olema Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $408.96 Million | +61.08% |
| 2023-12-31 | $253.90 Million | +28.52% |
| 2022-12-31 | $197.55 Million | -30.58% |
| 2021-12-31 | $284.57 Million | -15.84% |
| 2020-12-31 | $338.14 Million | +3291.78% |
| 2019-12-31 | $-10.59 Million | -68.75% |
| 2018-12-31 | $-6.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Olema Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42866000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $143.00K | 0.03% |
| Other Components | $843.92 Million | 206.36% |
| Total Equity | $408.96 Million | 100.00% |
Olema Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Olema Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Union Holdings Ltd
SHE:000036
|
$1.15 Billion |
|
ABOUT YOU Holding AG
F:YOU
|
$1.15 Billion |
|
Beijing Haitian Ruisheng Science Technology Ltd
SHG:688787
|
$1.15 Billion |
|
Cangzhou Dahua Co Ltd
SHG:600230
|
$1.15 Billion |
|
Energy Resources of Australia Ltd
AU:ERA
|
$1.15 Billion |
|
Evotec SE ADR
NASDAQ:EVO
|
$1.15 Billion |
|
Arcos Dorados Holdings Inc
NYSE:ARCO
|
$1.15 Billion |
|
Fujian Septwolves Industry Co Ltd
SHE:002029
|
$1.15 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Olema Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 253,895,000 to 408,964,000, a change of 155,069,000 (61.1%).
- Net loss of 129,474,000 reduced equity.
- New share issuances of 266,288,000 increased equity.
- Other comprehensive income decreased equity by 204,000.
- Other factors increased equity by 18,459,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-129.47 Million | -31.66% |
| Share Issuances | $266.29 Million | +65.11% |
| Other Comprehensive Income | $-204.00K | -0.05% |
| Other Changes | $18.46 Million | +4.51% |
| Total Change | $- | 61.08% |
Book Value vs Market Value Analysis
This analysis compares Olema Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.45 | $14.32 | x |
| 2019-12-31 | $-0.26 | $14.32 | x |
| 2020-12-31 | $8.60 | $14.32 | x |
| 2021-12-31 | $7.20 | $14.32 | x |
| 2022-12-31 | $4.94 | $14.32 | x |
| 2023-12-31 | $5.61 | $14.32 | x |
| 2024-12-31 | $6.96 | $14.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Olema Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.10x
- Recent ROE (-31.66%) is below the historical average (-21.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.57 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.26 Million |
| 2020 | -6.54% | 0.00% | 0.00x | 1.01x | $-55.93 Million |
| 2021 | -24.98% | 0.00% | 0.00x | 1.04x | $-99.55 Million |
| 2022 | -51.93% | 0.00% | 0.00x | 1.09x | $-122.34 Million |
| 2023 | -38.07% | 0.00% | 0.00x | 1.09x | $-122.04 Million |
| 2024 | -31.66% | 0.00% | 0.00x | 1.10x | $-170.37 Million |
Industry Comparison
This section compares Olema Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Olema Pharmaceuticals Inc (OLMA) | $307.49 Million | 0.00% | 0.15x | $1.15 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen rec… Read more